# Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

> **NCT06647680** · PHASE2 · RECRUITING · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 35 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **DRUG:** Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles

## Key facts

- **NCT ID:** NCT06647680
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647680, "Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06647680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*